Drug Profile


Alternative Names: AMG-162; Prolia; Ranmark; Xgeva

Latest Information Update: 26 May 2017

Price : $50

At a glance

  • Originator Amgen
  • Developer Amgen; Daiichi Sankyo Company; European Thoracic Oncology Platform; GlaxoSmithKline
  • Class Antineoplastics; Monoclonal antibodies; Osteoporosis therapies
  • Mechanism of Action RANK ligand inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant hypercalcaemia; Bone cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Bone disorders; Bone metastases; Male osteoporosis; Osteoporosis; Postmenopausal osteoporosis
  • Registered Bone cancer; Malignant hypercalcaemia
  • Preregistration Rheumatoid arthritis
  • Phase III Breast cancer; Corticosteroid-induced osteoporosis; Non-small cell lung cancer; Osteogenesis imperfecta
  • No development reported Multiple myeloma

Most Recent Events

  • 04 Apr 2017 Preregistration for Bone disorders (First-line therapy) in European Union (SC)
  • 04 Apr 2017 Preregistration for Bone disorders (First-line therapy) in USA (SC)
  • 01 Apr 2017 Pooled analysis data from the FREEDOM and FREEDOM extension phase III trials in Postmenopausal osteoporosis presented at the 99th Annual Meeting of the Endocrine Society (ENDO-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top